OncoMatch/Clinical Trials/NCT06086704
Study of 18F-FFNP Breast PET/MRI
Is NCT06086704 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including 18F-fluorofuranylnorprogesterone and Positron Emissions Tomography / Magnetic Resonance Imaging for breast cancer.
Treatment: 18F-fluorofuranylnorprogesterone · Positron Emissions Tomography / Magnetic Resonance Imaging · Anastrozole · FDA-approved gadolinium-based intravenous contrast agent — This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The overall purpose of this research is to test the efficacy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy and to determine the quantitative reliability of 18F-FFNP breast PET/MRI in patients with newly diagnosed PR+ primary breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: PR (PGR) overexpression (PR-positive)
Biopsy-proven PR-positive invasive breast cancer
Excluded: HER2 (ERBB2) overexpression
HER2-positive breast cancer, as defined by immunohistochemical staining 3+ OR positive by in situ hybridization (Group 2 only)
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Patients who have completed neoadjuvant chemotherapy ... for the current biopsy-proven malignancy
Cannot have received: endocrine therapy
Patients who have completed ... endocrine therapy ... for the current biopsy-proven malignancy
Cannot have received: targeted therapy
Patients who have completed ... targeted therapy ... for the current biopsy-proven malignancy
Cannot have received: surgical resection
Patients who have completed ... surgical resection ... for the current biopsy-proven malignancy
Cannot have received: radiation therapy
Patients who have completed ... radiation ... for the current biopsy-proven malignancy
Cannot have received: aromatase inhibitor (anastrozole)
Patients who are planning to undergo anastrozole as standard of care neoadjuvant therapy
Cannot have received: aromatase inhibitor
Patients who are currently taking aromatase inhibitors
Cannot have received: ER antagonist (tamoxifen, raloxifene)
Patients who are currently taking ... ER antagonists (tamoxifen, raloxifene)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UW Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify